These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 19854709)

  • 1. iTRAQ-based proteomic identification of leucine-rich alpha-2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases.
    Serada S; Fujimoto M; Ogata A; Terabe F; Hirano T; Iijima H; Shinzaki S; Nishikawa T; Ohkawara T; Iwahori K; Ohguro N; Kishimoto T; Naka T
    Ann Rheum Dis; 2010 Apr; 69(4):770-4. PubMed ID: 19854709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leucine-rich α2 -glycoprotein as a potential biomarker for joint inflammation during anti-interleukin-6 biologic therapy in rheumatoid arthritis.
    Fujimoto M; Serada S; Suzuki K; Nishikawa A; Ogata A; Nanki T; Hattori K; Kohsaka H; Miyasaka N; Takeuchi T; Naka T
    Arthritis Rheumatol; 2015 May; 67(8):2056-60. PubMed ID: 25917892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of serum leucine-rich alpha-2 glycoprotein as a disease activity biomarker in patients with rheumatoid arthritis.
    Ha YJ; Kang EJ; Lee SW; Lee SK; Park YB; Song JS; Choi ST
    J Korean Med Sci; 2014 Sep; 29(9):1199-204. PubMed ID: 25246736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ELISA for human serum leucine-rich alpha-2-glycoprotein-1 employing cytochrome c as the capturing ligand.
    Weivoda S; Andersen JD; Skogen A; Schlievert PM; Fontana D; Schacker T; Tuite P; Dubinsky JM; Jemmerson R
    J Immunol Methods; 2008 Jul; 336(1):22-9. PubMed ID: 18436231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis.
    Serada S; Fujimoto M; Terabe F; Iijima H; Shinzaki S; Matsuzaki S; Ohkawara T; Nezu R; Nakajima S; Kobayashi T; Plevy SE; Takehara T; Naka T
    Inflamm Bowel Dis; 2012 Nov; 18(11):2169-79. PubMed ID: 22374925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum leucine-rich α2-glycoprotein is a useful biomarker for monitoring disease activity in patients with adult-onset Still's disease.
    Ha YJ; Kang EJ; Lee SW; Park YB; Lee SK; Song JS; Choi ST
    Scand J Rheumatol; 2015; 44(5):399-403. PubMed ID: 26079682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease.
    Yoshimura T; Mitsuyama K; Sakemi R; Takedatsu H; Yoshioka S; Kuwaki K; Mori A; Fukunaga S; Araki T; Morita M; Tsuruta K; Yamasaki H; Torimura T
    Mediators Inflamm; 2021; 2021():8825374. PubMed ID: 33623482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis.
    Shinzaki S; Matsuoka K; Iijima H; Mizuno S; Serada S; Fujimoto M; Arai N; Koyama N; Morii E; Watanabe M; Hibi T; Kanai T; Takehara T; Naka T
    J Crohns Colitis; 2017 Jan; 11(1):84-91. PubMed ID: 27466171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leucine-Rich Alpha-2 Glycoprotein in Monitoring Disease Activity and Intestinal Stenosis in Inflammatory Bowel Disease.
    Yoshida T; Shimodaira Y; Fukuda S; Watanabe N; Koizumi S; Matsuhashi T; Onochi K; Iijima K
    Tohoku J Exp Med; 2022 Jul; 257(4):301-308. PubMed ID: 35598974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteomic analysis of coronary sinus serum reveals leucine-rich α2-glycoprotein as a novel biomarker of ventricular dysfunction and heart failure.
    Watson CJ; Ledwidge MT; Phelan D; Collier P; Byrne JC; Dunn MJ; McDonald KM; Baugh JA
    Circ Heart Fail; 2011 Mar; 4(2):188-97. PubMed ID: 21282491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment.
    Ziolkowska M; Kurowska M; Radzikowska A; Luszczykiewicz G; Wiland P; Dziewczopolski W; Filipowicz-Sosnowska A; Pazdur J; Szechinski J; Kowalczewski J; Rell-Bakalarska M; Maslinski W
    Arthritis Rheum; 2002 Jul; 46(7):1744-53. PubMed ID: 12124857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in MiRNA-5196 Expression as a Potential Biomarker of Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis Patients.
    Ciechomska M; Bonek K; Merdas M; Zarecki P; Swierkot J; Gluszko P; Bogunia-Kubik K; Maslinski W
    Arch Immunol Ther Exp (Warsz); 2018 Oct; 66(5):389-397. PubMed ID: 29744553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum proteomic analysis identifies interleukin 16 as a biomarker for clinical response during early treatment of rheumatoid arthritis.
    Murota A; Suzuki K; Kassai Y; Miyazaki T; Morita R; Kondo Y; Takeshita M; Niki Y; Yoshimura A; Takeuchi T
    Cytokine; 2016 Feb; 78():87-93. PubMed ID: 26700586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis.
    Capsoni F; Sarzi-Puttini P; Atzeni F; Minonzio F; Bonara P; Doria A; Carrabba M
    Arthritis Res Ther; 2005; 7(2):R250-5. PubMed ID: 15743471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leucine-rich α2-glycoprotein as the acute-phase reactant to detect systemic juvenile idiopathic arthritis disease activity during anti-interleukin-6 blockade therapy: A case series.
    Shimizu M; Nakagishi Y; Inoue N; Mizuta M; Yachie A
    Mod Rheumatol; 2017 Sep; 27(5):833-837. PubMed ID: 28094589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study.
    Shinzaki S; Matsuoka K; Tanaka H; Takeshima F; Kato S; Torisu T; Ohta Y; Watanabe K; Nakamura S; Yoshimura N; Kobayashi T; Shiotani A; Hirai F; Hiraoka S; Watanabe M; Matsuura M; Nishimoto S; Mizuno S; Iijima H; Takehara T; Naka T; Kanai T; Matsumoto T
    J Gastroenterol; 2021 Jun; 56(6):560-569. PubMed ID: 33942166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
    Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis.
    Ingegnoli F; Fantini F; Griffini S; Soldi A; Meroni PL; Cugno M
    Clin Exp Rheumatol; 2010; 28(2):254-7. PubMed ID: 20483049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis.
    Gonzalez-Gay MA; Garcia-Unzueta MT; Gonzalez-Juanatey C; Miranda-Filloy JA; Vazquez-Rodriguez TR; De Matias JM; Martin J; Dessein PH; Llorca J
    Clin Exp Rheumatol; 2008; 26(2):311-6. PubMed ID: 18565254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis.
    Gonzalez-Gay MA; Garcia-Unzueta MT; De Matias JM; Gonzalez-Juanatey C; Garcia-Porrua C; Sanchez-Andrade A; Martin J; Llorca J
    Clin Exp Rheumatol; 2006; 24(4):373-9. PubMed ID: 16956426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.